Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 17, 2017 - Issue 7
Submit an article Journal homepage
313
Views
10
CrossRef citations to date
0
Altmetric
Drug Profile

Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA

Andrew J. LeesReta Lila Weston Institute for Neurological Studies, UCL, London, UKCorrespondence[email protected]
View further author information
,
Joaquim FerreiraCentro de Estudos Egas Moniz, Hospital de Santa Maria, Lisbon, PortugalORCID Iconhttp://orcid.org/0000-0003-3950-5113View further author information
ORCID Icon,
Olivier RascolDepartments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC 1436, NS-Park/FCRIN network and NeuroToul COEN Center, INSERM, Toulouse University Hospital and Toulouse3 University, Toulouse, FranceView further author information
,
Heinz ReichmannDepartment of Neurology, Technische Universitaet Dresden, Dresden, GermanyView further author information
,
Fabrizio StocchiInstitute of Neurology, IRCCS San Raffaele Pisana, Rome, ItalyView further author information
,
Eduardo TolosaNeurology Service, Centro de Investigación Biomódica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain​​​​View further author information
&
Werner PoeweDepartment of Neurology, Innsbruck Medical University, Innsbruck, AustriaView further author information
 show all
Pages 649-659 | Received 04 Nov 2016, Accepted 25 May 2017, Published online: 05 Jun 2017

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Matthew Feldman & Jason Margolesky. (2023) Opicapone for the treatment of Parkinson’s disease: a review. International Journal of Neuroscience 133:5, pages 532-543.
Read now
Peter Jenner, José-Francisco Rocha, Joaquim J Ferreira, Olivier Rascol & Patrício Soares-da-Silva. (2021) Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone. Expert Review of Neurotherapeutics 21:9, pages 1019-1033.
Read now
Miren Ettcheto, Oriol Busquets, Elena Sánchez-Lopez, Amanda Cano, Patricia R. Manzine, Ester Verdaguer, Jordi Olloquequi, Carme Auladell, Jaume Folch & Antoni Camins. (2020) The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease. Expert Opinion on Drug Discovery 15:9, pages 993-1003.
Read now
Nataša Dragašević-Mišković, Igor Petrović, Iva Stanković & Vladimir S. Kostić. (2019) Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients. Expert Opinion on Pharmacotherapy 20:2, pages 219-230.
Read now

Articles from other publishers (6)

Natalie E Allen, Colleen G Canning, Lorena Rosa S Almeida, Bastiaan R Bloem, Samyra HJ Keus, Niklas Löfgren, Alice Nieuwboer, Geert SAF Verheyden, Tiê P Yamato & Catherine Sherrington. (2022) Interventions for preventing falls in Parkinson's disease. Cochrane Database of Systematic Reviews 2022:8.
Crossref
Diego Santos García, Gustavo Fernández Pajarín, Juan Manuel Oropesa-Ruiz, Francisco Escamilla Sevilla, Raúl Rashid Abdul Rahim López & José Guillermo Muñoz Enríquez. (2022) Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study. Brain Sciences 12:3, pages 383.
Crossref
Zhaoming Song, Jie Zhang, Tao Xue, Yanbo Yang, Da Wu, Zhouqing Chen, Wanchun You & Zhong Wang. (2021) Different Catechol-O-Methyl Transferase Inhibitors in Parkinson's Disease: A Bayesian Network Meta-Analysis. Frontiers in Neurology 12.
Crossref
Andrew Lees, Joaquim J. Ferreira, José-Francisco Rocha, Olivier Rascol, Werner Poewe, Helena Gama & Patrício Soares-da-Silva. (2019) Safety Profile of Opicapone in the Management of Parkinson’s Disease. Journal of Parkinson's Disease 9:4, pages 733-740.
Crossref
Pedro Merino. 2019. Chemical Biology of Neurodegeneration. Chemical Biology of Neurodegeneration 325 357 .
Joaquim J. FerreiraAndrew J. LeesWerner PoeweOlivier RascolJosé-Francisco RochaBirgit KellerPatricio Soares-da-Silva. (2018) Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology 90:21.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.